RNS
Reach
14 February 2024
Futura Medical
plc
("Futura" or the
"Company")
Eroxon to be available on
prescription
as well as over the counter
Futura Medical plc (AIM: FUM), the
consumer healthcare company behind Eroxon, that specialises in the
development and global commercialisation of innovative
and clinically proven sexual health products, confirms that
its lead product, Eroxon, will be available on prescription in
England and Wales for the treatment of Erectile Dysfunction ("ED")
with effect from 1st March 2024. Eroxon is also
available without a doctor's prescription having launched in the UK
in March 2023.
James Barder, CEO of Futura, commented:
"This milestone builds on the strong progress the Company has
made since the initial launch of Eroxon in the UK and is a further
step in improving availability of Eroxon, providing access by
prescription for men with ED as well as over the
counter."
Contacts:
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
|
|
|
|
|
Alma Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally
across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men
under 40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.